ATE241341T1 - Stabilisierte pharmazeutische zusammensetzung - Google Patents

Stabilisierte pharmazeutische zusammensetzung

Info

Publication number
ATE241341T1
ATE241341T1 AT98307200T AT98307200T ATE241341T1 AT E241341 T1 ATE241341 T1 AT E241341T1 AT 98307200 T AT98307200 T AT 98307200T AT 98307200 T AT98307200 T AT 98307200T AT E241341 T1 ATE241341 T1 AT E241341T1
Authority
AT
Austria
Prior art keywords
stabilized pharmaceutical
pharmaceutical composition
agent
light
ultraviolet rays
Prior art date
Application number
AT98307200T
Other languages
German (de)
English (en)
Inventor
Makoto Fukuta
Hiroki Itoh
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE241341T1 publication Critical patent/ATE241341T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98307200T 1997-09-10 1998-09-07 Stabilisierte pharmazeutische zusammensetzung ATE241341T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24577897 1997-09-10

Publications (1)

Publication Number Publication Date
ATE241341T1 true ATE241341T1 (de) 2003-06-15

Family

ID=17138687

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98307200T ATE241341T1 (de) 1997-09-10 1998-09-07 Stabilisierte pharmazeutische zusammensetzung

Country Status (5)

Country Link
US (1) US6187340B1 (fr)
EP (1) EP0901787B1 (fr)
AT (1) ATE241341T1 (fr)
CA (1) CA2247011A1 (fr)
DE (1) DE69815003T2 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208906A1 (en) * 1999-07-12 2004-10-21 Daiichi Suntory Pharma Co., Ltd. Pharmaceutical composition for topical administration
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
HU229295B1 (en) * 1999-08-04 2013-10-28 Astellas Pharma Inc Stable medicinal compositions for oral use
AU1304501A (en) 1999-11-11 2001-06-06 Kyorin Pharmaceutical Co. Ltd. Oral solid preparation
US7201891B1 (en) * 2000-05-19 2007-04-10 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical preparation for the diagnosis of helicobacter pylori infection
WO2002060446A1 (fr) 2001-01-29 2002-08-08 Shionogi & Co., Ltd. Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
JP2005508358A (ja) * 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20050123484A1 (en) * 2003-10-02 2005-06-09 Collegium Pharmaceutical, Inc. Non-flammable topical anesthetic liquid aerosols
US20060188449A1 (en) * 2003-10-03 2006-08-24 Jane Hirsh Topical aerosol foams
NL1025311C2 (nl) * 2004-01-23 2005-07-27 Kaak Johan H B Inrichting en werkwijze voor het vormen van een langwerpige deegportie.
KR20120136430A (ko) * 2004-04-08 2012-12-18 교와 핫꼬 기린 가부시키가이샤 안정성이 향상된 고형 제제 및 그 제조 방법
EP1742630A4 (fr) * 2004-04-16 2010-01-20 Santarus Inc Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP2009503020A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
CA2626134C (fr) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
WO2007052592A1 (fr) * 2005-10-31 2007-05-10 Kowa Co., Ltd. Preparation pharmaceutique ayant une photostabilite excellente
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
CN1793905B (zh) * 2005-12-30 2010-12-08 江中药业股份有限公司 一种同时检测盐酸氯哌丁与马来酸氯苯那敏组合物的方法
US8940796B2 (en) * 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
US20070231387A1 (en) * 2006-04-04 2007-10-04 Luigi Levi Film-coated solid dosage forms
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070254027A1 (en) 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
MX2008013827A (es) * 2006-05-09 2008-11-10 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual.
KR101370245B1 (ko) * 2006-05-23 2014-03-05 린텍 가부시키가이샤 점접착제 조성물, 점접착 시트 및 반도체장치의 제조방법
EP2037927B1 (fr) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibansérine dans le traitement de l'incontinence urinaire et des maladies associées
US20080014274A1 (en) * 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
WO2008006838A1 (fr) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Utilisation de flibansérine pour le traitement de troubles sexuels chez les femmes
US9005652B2 (en) * 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090045945A (ko) * 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
CA2667682A1 (fr) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprenant des agents d'inhibition de la pompe a protons labiles d'acide, au moins un autre agent pharmaceutiquement actif et leurs procedes d'utilisation
KR20080047990A (ko) 2006-11-27 2008-05-30 린텍 가부시키가이샤 점접착제 조성물, 점접착 시트 및 반도체 장치의 제조방법
JPWO2008081835A1 (ja) * 2006-12-28 2010-04-30 クオリカプス株式会社 水濡れインジケーターおよびタイムインジケーター
WO2008090742A1 (fr) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University Animal non humain pour un modèle de maladie des yeux
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2008156027A1 (fr) * 2007-06-20 2008-12-24 Qualicaps Co., Ltd. Composition de revêtement non transparent
CL2008002693A1 (es) * 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
US20100021607A1 (en) * 2008-07-22 2010-01-28 Van Lengerich Bernhard H Fruit products containing omega-3 fatty acids
TW201431552A (zh) 2008-07-28 2014-08-16 Takeda Pharmaceutical 醫藥組成物
AU2010254831B2 (en) * 2009-06-05 2015-11-19 General Mills, Inc. Encapsulated omega-3 fatty acids for baked goods production
US8962064B2 (en) 2011-02-28 2015-02-24 Basf Se Production of pulverulent coating compositions for stable protective coatings for pharmaceutical dosage forms
BR112013020877B1 (pt) 2011-02-28 2020-06-02 Basf Se Processo para produzir composições de revestimento pulverulentas
EP2994204A4 (fr) * 2013-05-07 2017-01-11 Board of Regents, The University of Texas System Système de destruction de médicaments
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
WO2018002673A1 (fr) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii
CN109475557B (zh) * 2016-07-27 2022-01-07 日本脏器制药株式会社 含有甲氨蝶呤的薄膜包衣片
RU2681848C2 (ru) * 2017-07-14 2019-03-13 Михаил Юрьевич Савинов Фармацевтический препарат и способ его получения

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3390049A (en) * 1964-12-23 1968-06-25 Smith Kline French Lab Pharmaceutical tablets coated with wax-free ammonia solubilized water soluble shellac
JPS55162715A (en) * 1979-06-04 1980-12-18 Takeda Chem Ind Ltd Preparation of enteric granule
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4636261A (en) * 1984-10-24 1987-01-13 Heinze Richard F Dry lake system
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
HU206824B (en) * 1990-08-24 1993-01-28 Biogal Gyogyszergyar Process for the production of a table crystallizing in the monoclinic system, which contains light-, heat-, and moisture- sensitive active agents
US5593691A (en) * 1993-06-03 1997-01-14 Marigen S.A. Biotenside solvents for pharmaceuticals and cosmetics

Also Published As

Publication number Publication date
US6187340B1 (en) 2001-02-13
CA2247011A1 (fr) 1999-03-10
DE69815003D1 (de) 2003-07-03
DE69815003T2 (de) 2004-04-01
EP0901787B1 (fr) 2003-05-28
EP0901787A1 (fr) 1999-03-17

Similar Documents

Publication Publication Date Title
ATE241341T1 (de) Stabilisierte pharmazeutische zusammensetzung
DE69509952D1 (de) Beschichtungen geeignet zur Absorption von Ultraviolettlicht
KR19980701899A (ko) 피리티온 함유 코팅 조성물의 변색 방지법
DE59106390D1 (de) Gegen Schädigung durch Licht, Wärme und Sauerstoff stabilisierte Ueberzugsmittel.
ES2060449T3 (es) Composicion de revestimiento en polvo que contiene una resina, un agente de curado y zinc.
FI955144L (fi) Päällystetyt farmaseuttiset koostumukset
ATE188471T1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzung
DE59806139D1 (de) Verwendung von Pyrimidinderivaten zur Herstellung eines Arzneimittels zur Prävention von Krebs
NO20022998D0 (no) Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
DE69202822D1 (de) Silikonmodifizierte wässrige Überzugszusammensetzung.
DE69630145D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
FI103050B1 (fi) Menetelmä N,O-sulfatoituja heparosaaneja sisältävän koostumuksen valmistamiseksi
DK0696326T3 (da) Anvendelse af NDV til fremstilling af et medikament til behandling af cancer
FI932395A7 (fi) Polymeerialustan ultraviolettisäteilystä johtuvan hajoamisen vähentämi nen
MX9201529A (es) Composiciones de revestimiento transparente curables con luz ultravioleta (uv) y procedimiento.
SG93820A1 (en) Photosensitizer, visible light curable resin composition using the same, and use of the composition
ES2131149T3 (es) Composicion de revestimiento transparente conductor y articulo moldeado transparente antiestatico.
AU5457994A (en) Ultraviolet light absorbing compounds, silicone compositions and methods for making same
DE60332561D1 (de) Hochreflexionspolyesterbeschichtung
DE69926379D1 (de) Verfahren zur herstellung von 2-(2,4-dihydroxyphenyl) or 2-(2,4-dialkoxyphenyl) -4,6-bisaryl-1,3,5-triazine
DE69414457D1 (de) Ultraviolettes Licht beständige antireflektierende Beschichtung
DE69828138D1 (de) Licht-absorbierendes polymer, zusammensetzung die licht-absorbierende beschichtungen bildet, licht-absorbierende beschichtungen und daraus hergestellte antireflektionsbeschichtungen
DE69608680D1 (de) Taxal derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DK0797634T3 (da) Maling med lav emissionsevne i varmestrålingsområdet
DE69630714D1 (de) Lichtemittierende Halbleitervorrichtung und deren Herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties